Editorial
Osteoarthritis. Your turn
Artrosis. Su turno
Montserrat Romera Baures
Servicio de Reumatología, Hospital Universitari de Bellvitge, l’Hospitalet de Llobregat, Barcelona, Spain
Read
4034
Timeswas read the article
1723
Total PDF
2311
Total HTML
Share statistics
array:23 [ "pii" => "S217357431730059X" "issn" => "21735743" "doi" => "10.1016/j.reumae.2017.03.001" "estado" => "S300" "fechaPublicacion" => "2017-05-01" "aid" => "1044" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología" "copyrightAnyo" => "2017" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Reumatol Clin. 2017;13:125-6" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 734 "formatos" => array:3 [ "EPUB" => 57 "HTML" => 479 "PDF" => 198 ] ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S1699258X17300864" "issn" => "1699258X" "doi" => "10.1016/j.reuma.2017.03.016" "estado" => "S300" "fechaPublicacion" => "2017-05-01" "aid" => "1044" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Reumatol Clin. 2017;13:125-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3701 "formatos" => array:3 [ "EPUB" => 210 "HTML" => 2404 "PDF" => 1087 ] ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "Artrosis. Su turno" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "125" "paginaFinal" => "126" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Osteoarthritis. Your turn" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Montserrat Romera Baures" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Montserrat" "apellidos" => "Romera Baures" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S217357431730059X" "doi" => "10.1016/j.reumae.2017.03.001" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S217357431730059X?idApp=UINPBA00004M" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X17300864?idApp=UINPBA00004M" "url" => "/1699258X/0000001300000003/v1_201704290027/S1699258X17300864/v1_201704290027/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2173574317300540" "issn" => "21735743" "doi" => "10.1016/j.reumae.2016.10.002" "estado" => "S300" "fechaPublicacion" => "2017-05-01" "aid" => "977" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Reumatol Clin. 2017;13:127-38" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 861 "formatos" => array:3 [ "EPUB" => 59 "HTML" => 569 "PDF" => 233 ] ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Special Article</span>" "titulo" => "Recommendations by the Spanish Rheumatology Society for the Management of Patients Diagnosed With Rheumatoid Arthritis who Cannot Be Treated With Methotrexate" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "127" "paginaFinal" => "138" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Documento de Recomendaciones de la Sociedad Española de Reumatología para el manejo clínico del paciente con artritis reumatoide que no puede utilizar metotrexato" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Rosario García-Vicuña, María Auxiliadora Martín-Martínez, María Rosa Gonzalez-Crespo, Jesús Tornero-Molina, Antonio Fernández-Nebro, Francisco Javier Blanco-García, Ricardo Blanco-Alonso, Sara Marsal-Barril" "autores" => array:9 [ 0 => array:2 [ "nombre" => "Rosario" "apellidos" => "García-Vicuña" ] 1 => array:2 [ "nombre" => "María Auxiliadora" "apellidos" => "Martín-Martínez" ] 2 => array:2 [ "nombre" => "María Rosa" "apellidos" => "Gonzalez-Crespo" ] 3 => array:2 [ "nombre" => "Jesús" "apellidos" => "Tornero-Molina" ] 4 => array:2 [ "nombre" => "Antonio" "apellidos" => "Fernández-Nebro" ] 5 => array:2 [ "nombre" => "Francisco Javier" "apellidos" => "Blanco-García" ] 6 => array:2 [ "nombre" => "Ricardo" "apellidos" => "Blanco-Alonso" ] 7 => array:2 [ "nombre" => "Sara" "apellidos" => "Marsal-Barril" ] 8 => array:1 [ "colaborador" => "in representation of the Scientific Committee of the work of Recommendations of the Spanish Society of Rheumatology for the clinical management of the patient with rheumatoid arthritis who cannot use methotrexate" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S1699258X16301310" "doi" => "10.1016/j.reuma.2016.10.002" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X16301310?idApp=UINPBA00004M" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574317300540?idApp=UINPBA00004M" "url" => "/21735743/0000001300000003/v1_201705040052/S2173574317300540/v1_201705040052/en/main.assets" ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "Osteoarthritis. Your turn" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "125" "paginaFinal" => "126" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "Montserrat Romera Baures" "autores" => array:1 [ 0 => array:3 [ "nombre" => "Montserrat" "apellidos" => "Romera Baures" "email" => array:1 [ 0 => "m.romera@bellvitgehospital.cat" ] ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Servicio de Reumatología, Hospital Universitari de Bellvitge, l’Hospitalet de Llobregat, Barcelona, Spain" "identificador" => "aff0005" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Artrosis. Su turno" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Although osteoarthritis (OA) is the most widespread rheumatic disease, with an estimated prevalence, according to the EPISER study, of 10% in Spain, its etiology is generally unknown. In contrast to other rheumatic diseases considered to be “more serious”, because of their effect on vital organs or the rapid development of joint destruction, it has, in many cases, been largely forgotten. Osteoarthritis is known to have a great impact on quality of life, on patient productivity and on the costs of the disease. It has been suggested that it will be the fourth major cause of disability by 2020, and is among the 25 foremost causes having the greatest impact on health according to the global burden of disease.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">There is a great variability in the utilization of different drugs for the treatment of the symptoms of OA. In a population-based study conducted in Catalonia, in northeastern Spain, with 238,536 participants, the drugs most frequently administered were chondroitin sulfate (21.2%), glucosamine (15.8%) and oral anti-inflammatory drugs (14.4%).<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> The researchers detected an increase in the incidence of the use of opioids and of cyclooxygenase 2 (COX-2) inhibitors during the study period (2006–2010). The authors conclude that the combination of different drugs is very common in the treatment of OA patients, and they alert us about the risk of possible drug interactions that can have a potential impact on safety, as well as an increase in the costs of the disease. The utilization of some of these agents may also have an effect on an increase in cardiovascular episodes in an OA population in which there is very probably a cardiovascular risk profile.</p><p id="par0015" class="elsevierStylePara elsevierViewall">Osteoarthritis was initially considered a single disease, but recent findings on its pathogenesis indicate that it is a condition with a phenotypic variety that includes metabolic, age-related, inflammatory and hormonal disorders, as well as the existence of previous lesions, among other causes. In some cases, there is a clear phenotype, but, on other occasions, the phenotypes overlap. Although OA is described as a noninflammatory disease, there is data in the literature that show that inflammation may contribute to the symptoms and to the progression of this condition.<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a> In OA there can be molecular anomalies or defined radiographic features much before the development of the clinical symptoms, that can take years or even decades before they are noted; it could be defined as an asymptomatic state of the disease. Both epidemiological and biological studies support the concept of metabolic OA, which, regardless of obesity or other known risk factors, links several components of metabolic syndrome such as hypertension and type 2 diabetes. An increase in the rate of mortality—mainly from cardiovascular causes—has been reported in OA patients.<a class="elsevierStyleCrossRefs" href="#bib0020"><span class="elsevierStyleSup">4,5</span></a> Genetic factors that have been associated with a greater severity of the progression of the disease have also been identified.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">Owing to the heterogeneity of OA, the Osteoarthritis Research Society International (OARSI) recommends stimulating the use of a standard nomenclature for its definition, which would serve as a basis to describe OA and be able to define the different phenotypes. One of the great challenges in research on OA is the lack of tools designed for detecting the disease at an early stage, identifying the risks of having this condition and predicting its progression. According to the OARSI, it would be important to establish tools analogous to the FRAX—developed to predict the risk of fracture in osteoporosis—to identify the disease at an early stage in its first preradiographic and/or molecular stages. Agreement on sensitive and specific diagnostic criteria would help in the development of disease-modifying therapies for this disorder that have proved to be so recalcitrant to date.<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">Following these recommendations and to facilitate the undertaking of research projects, the Spanish Society of Rheumatology (SER) has constituted the ARTROSER Working Group, whose main interest will be the study of this condition, which is highly prevalent in Spain. Its aim is to cover all of the forms in which the disease is expressed and the possible factors than can influence the health and quality of life of patients with OA, to subsequently work in its prevention and possible treatments.</p><p id="par0030" class="elsevierStylePara elsevierViewall">The major objective of the working groups of the SER is to make advances in our scientific understanding. They have been created so that all the interested members can collaborate in a specific aspect of rheumatology.</p><p id="par0035" class="elsevierStylePara elsevierViewall">One of the first initiatives proposed by ARTROSER was to coordinate a roundtable at the next congress of the Spanish Society of Rheumatology to be held in Bilbao. There, we will approach the subject of metabolic OA, the relationship to the Mediterranean diet and inflammation as a model for the prevention and treatment of OA, and suggest as an objective the design of a Spanish cohort for the study of this disease.</p><p id="par0040" class="elsevierStylePara elsevierViewall">Osteoarthritis is a prevalent and disabling condition that involves an organ—the joint—and leads to the outcome of joint failure. Early detection of OA, as well as the characterization of the different phenotypes, are crucial elements for understanding the process of this disorder and will help us to identify new treatments that will be effective both in the treatment of the symptoms and in modifying the course of the disease.</p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Romera Baures M. Artrosis. Su turno. Reumatol Clin. 2017. <span class="elsevierStyleInterRef" id="intr0005" href="doi:10.1016/j.reuma.2017.03.016">http://dx.doi.org/10.1016/j.reuma.2017.03.016</span></p>" ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:7 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C.J. Murray" 1 => "T. Vos" 2 => "R. Lozano" 3 => "M. Naghavi" 4 => "A.D. Flaxman" 5 => "C. Michaud" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(12)61689-4" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2012" "volumen" => "380" "paginaInicial" => "2197" "paginaFinal" => "2223" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23245608" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Drug utilization in patients with OA: a population-based study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "N. Wilson" 1 => "L. Sanchez-Riera" 2 => "R. Morros" 3 => "A. Diez-Perez" 4 => "M. Kassim Javaid" 5 => "C. Cooper" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/rheumatology/keu403" "Revista" => array:6 [ "tituloSerie" => "Rheumatology" "fecha" => "2015" "volumen" => "54" "paginaInicial" => "860" "paginaFinal" => "867" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25339639" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Adipokines and osteoarthritis: novel molecules involved in the pathogenesis and progression of disease" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "J. Conde" 1 => "M. Scotece" 2 => "R. Gómez" 3 => "V. Lopez" 4 => "J.J. Gomez-Reino" 5 => "O. Gualillo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1155/2011/203901" "Revista" => array:5 [ "tituloSerie" => "Arthritis" "fecha" => "2011" "volumen" => "2011" "paginaInicial" => "203901" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22046513" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "E. Nuesch" 1 => "P. Dieppe" 2 => "S. Reichenbach" 3 => "S. Williams" 4 => "S. Iff" 5 => "P. Jüni" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "BMJ" "fecha" => "2011" "volumen" => "342" "paginaInicial" => "d1165" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21385807" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:3 [ "comentario" => "[Epub ahead of print]" "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "High prevalence of cardiovascular co-morbidities in patients with symptomatic knee or hand osteoarthritis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Calvet" 1 => "C. Orellana" 2 => "M. Larrosa" 3 => "N. Navarro" 4 => "J.J. Chillarón" 5 => "J. Pedro-Botet" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3109/03009742.2015.1054875" "Revista" => array:6 [ "tituloSerie" => "Scand J Rheumatol" "fecha" => "2015" "paginaInicial" => "1" "paginaFinal" => "4" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16467033" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0016508511006226" "estado" => "S300" "issn" => "00165085" ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Improved prediction of knee osteoarthritis progression by genetic polymorphisms: the Arthrotest study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "F.J. Blanco" 1 => "I. Möller" 2 => "M. Romera" 3 => "A. Rozadilla" 4 => "J.A. Sánchez-Lázaro" 5 => "A. Rodríguez" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Rheumatology (Oxford)" "fecha" => "2015" "volumen" => "54" "paginaInicial" => "1236" "paginaFinal" => "1243" ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "V.B. Kraus" 1 => "F.J. Blanco" 2 => "M. Englund" 3 => "M.A. Karsdal" 4 => "L.S. Lohmander" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.116/j.joca.2015.03.036" "Revista" => array:6 [ "tituloSerie" => "Osteoarthritis Cartilage" "fecha" => "2015" "volumen" => "23" "paginaInicial" => "1233" "paginaFinal" => "1241" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25865392" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/21735743/0000001300000003/v1_201705040052/S217357431730059X/v1_201705040052/en/main.assets" "Apartado" => array:4 [ "identificador" => "17335" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Editorial" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/21735743/0000001300000003/v1_201705040052/S217357431730059X/v1_201705040052/en/main.pdf?idApp=UINPBA00004M&text.app=https://reumatologiaclinica.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S217357431730059X?idApp=UINPBA00004M" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 10 | 14 | 24 |
| 2024 October | 34 | 32 | 66 |
| 2024 September | 33 | 14 | 47 |
| 2024 August | 55 | 33 | 88 |
| 2024 July | 34 | 18 | 52 |
| 2024 June | 33 | 29 | 62 |
| 2024 May | 30 | 20 | 50 |
| 2024 April | 33 | 17 | 50 |
| 2024 March | 36 | 37 | 73 |
| 2024 February | 31 | 21 | 52 |
| 2024 January | 26 | 25 | 51 |
| 2023 December | 22 | 16 | 38 |
| 2023 November | 45 | 26 | 71 |
| 2023 October | 37 | 27 | 64 |
| 2023 September | 35 | 28 | 63 |
| 2023 August | 32 | 14 | 46 |
| 2023 July | 22 | 20 | 42 |
| 2023 June | 30 | 20 | 50 |
| 2023 May | 31 | 18 | 49 |
| 2023 April | 20 | 5 | 25 |
| 2023 March | 33 | 29 | 62 |
| 2023 February | 45 | 31 | 76 |
| 2023 January | 32 | 10 | 42 |
| 2022 December | 40 | 30 | 70 |
| 2022 November | 37 | 24 | 61 |
| 2022 October | 41 | 38 | 79 |
| 2022 September | 38 | 34 | 72 |
| 2022 August | 27 | 37 | 64 |
| 2022 July | 21 | 39 | 60 |
| 2022 June | 28 | 14 | 42 |
| 2022 May | 37 | 34 | 71 |
| 2022 April | 25 | 42 | 67 |
| 2022 March | 35 | 42 | 77 |
| 2022 February | 36 | 25 | 61 |
| 2022 January | 35 | 41 | 76 |
| 2021 December | 23 | 39 | 62 |
| 2021 November | 21 | 35 | 56 |
| 2021 October | 57 | 54 | 111 |
| 2021 September | 37 | 41 | 78 |
| 2021 August | 22 | 33 | 55 |
| 2021 July | 18 | 28 | 46 |
| 2021 June | 28 | 21 | 49 |
| 2021 May | 37 | 53 | 90 |
| 2021 April | 80 | 64 | 144 |
| 2021 March | 48 | 35 | 83 |
| 2021 February | 37 | 16 | 53 |
| 2021 January | 26 | 24 | 50 |
| 2020 December | 49 | 22 | 71 |
| 2020 November | 24 | 17 | 41 |
| 2020 October | 24 | 17 | 41 |
| 2020 September | 38 | 25 | 63 |
| 2020 August | 23 | 19 | 42 |
| 2020 July | 13 | 19 | 32 |
| 2020 June | 29 | 29 | 58 |
| 2020 May | 19 | 11 | 30 |
| 2020 April | 26 | 13 | 39 |
| 2020 March | 13 | 6 | 19 |
| 2020 February | 1 | 0 | 1 |
| 2018 September | 0 | 1 | 1 |
| 2018 May | 3 | 1 | 4 |
| 2018 April | 51 | 10 | 61 |
| 2018 March | 61 | 9 | 70 |
| 2018 February | 36 | 16 | 52 |
| 2018 January | 35 | 8 | 43 |
| 2017 December | 25 | 16 | 41 |
| 2017 November | 27 | 7 | 34 |
| 2017 October | 17 | 8 | 25 |
| 2017 September | 21 | 8 | 29 |
| 2017 August | 28 | 9 | 37 |
| 2017 July | 28 | 16 | 44 |
| 2017 June | 70 | 41 | 111 |
| 2017 May | 77 | 48 | 125 |
Show all
